乳腺癌中GST-π、TOPO II的表达及临床意义

Expression and Significance of GST-π and TOPO II in Breast Cancer

目的 从细胞水平探讨乳腺癌耐药机制 ,以期为选择化疗方案提供参考 ,获得更有效的化疗效果。方法 应用免疫组化S -P法 ,对乳腺癌的主要耐药指标GST -π、TOPOⅡ进行检测 ,并结合临床分期进行研究。结果 (1)乳腺癌中GST -π表达率为 6 3.6 % (2 8/4 4) ,临床Ⅲ期表达率显著高于临床Ⅰ、Ⅱ期。 (2 )TOPOⅡ表达率为 47.7% (2 1/4 4) ,临床Ⅲ期表达率显著低于Ⅰ、Ⅱ期。 (3)TOPOⅡ与GST -π表达关系间无明显相关性 ,说明它们各自的表达从不同方面对肿瘤耐药起作用。结论 在乳腺癌化疗药物选择时 ,联合检测GST -π、TOPOⅡ的表达具有指导作用 ,对预后的判断有参考价值。

Objective To investigate the expression of GST-π and TOPO Ⅱ and their possible roles in breast cancer. Methods In forty-four cases of breast cancer specimens were stained immunohistochemically for GST-π and TOPO Ⅱ using respective antibody, and the results were correlated with tumor clinic stages.Results The expression of GST-π and TOPO Ⅱ in breast cancer were 63.6%,47.7% respectively, and the expression of GST-π and TOPO Ⅱ was correlate with clinic stages Ⅲ/Ⅰ,Ⅱ, the expression of GST-π was not related to that of TOPO Ⅱ.Conclusion A combined analysis of the expression of GST-π and TOPO Ⅱ in breast cancer may contribute to the selection of drug in chemotherapy and prognosis evaluation of breast cancer.